Bryan D. Smith

发表

Activase Region on Chloroplast Ribulose-1,5-bisphosphate Carboxylase/Oxygenase

A. Portis, R. J. Spreitzer, Carolyn M Ott, 2000, The Journal of Biological Chemistry.

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

J. Condeelis, Xiaoming Chen, Joan G. Jones, 2017, Molecular Cancer Therapeutics.

The Selective Tie 2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie 2 Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

J. Condeelis, Xiaoming Chen, Joan G. Jones, 2017 .

Theoretical, thermal, and coordination chemistry of the amphoteric thiazate (NSO)1 ion

D. S. Bohle, C. Hung, Bryan D. Smith, 2005 .

Discovery of Acyl Ureas as Highly Selective Small Molecule CSF1R Kinase Inhibitors.

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Functional and structural analyses of N-acylsulfonamide-linked dinucleoside inhibitors of RNase A

R. Raines, K. Acharya, N. Thiyagarajan, 2011, The FEBS journal.

Synthesis and Characterization of Isostructural Metalloporphyrin Chalconitrosyl Complexes Ru(TTP)(NE)Cl (E = O, S) and a Remarkable Thionitrosyl/Nitrite --> Nitrosyl/Thiazate Transformation.

A. Powell, D. S. Bohle, C. Hung, 1997, Inorganic chemistry.

Genetic selection for critical residues in ribonucleases.

R. Raines, Bryan D. Smith, 2006, Journal of molecular biology.

Biomimetic Synthesis of the Putative Cytotoxin Peroxynitrite, ONOO-, and Its Characterization as a Tetramethylammonium Salt

D. S. Bohle, S. Paulson, B. Hansert, 1994 .

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.

J. D. de Groot, D. Flynn, S. Park, 2016, Neuro-oncology.

Potent Inhibition of Ribonuclease A by Oligo(vinylsulfonic Acid)*

R. Raines, M. Soellner, Bryan D. Smith, 2003, Journal of Biological Chemistry.

Abstract PR01: Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models

Michael D. Kaufman, D. Flynn, S. Wise, 2015 .

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

R. Larson, K. Bhalla, O. Rosen, 2016, Haematologica.

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

L. Stewart, R. V. van Etten, T. Haack, 2011, Cancer cell.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Stacie L. Bulfer, O. Rosen, M. Heinrich, 2019, Cancer cell.

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

B. Druker, M. Deininger, J. Tyner, 2011, Cancer research.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015, Cancer cell.

Inhibition of RAF Isoforms and Active Dimers by LY 3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Graphical

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015 .

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

L. Stewart, Michael D. Kaufman, D. Flynn, 2015, Molecular Cancer Therapeutics.

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.

Michael D. Kaufman, Hidong Kim, M. Feese, 2010, Bioorganic & medicinal chemistry letters.

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Michael D. Kaufman, L. Davis, R. Ruiz-Soto, 2021, Molecular Cancer Therapeutics.

Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis

C. Serrano, Anu Gupta, Jarnail Singh, 2021, Molecular Cancer Therapeutics.

Effective Inhibition of c-MET-mediated Signaling, Growth, and Migration of Ovarian Cancer Cells is Influenced by the Ovarian Tissue Microenvironment

Yan Zhou, A. Godwin, Michael D. Kaufman, 2013, Oncogene.

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation

M. Berger, H. Kantarjian, J. Cortes, 2011 .

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

M. Ladanyi, A. Drilon, R. Somwar, 2020, Communications Biology.

Synthesis, structure and ligand exchange reactions of Ru(TTP)(NO)(OMe)

D. S. Bohle, Bryan D. Smith, P. Goodson, 1996 .

Site-specific folate conjugation to a cytotoxic protein.

R. Raines, J. J. Higgin, Bryan D. Smith, 2011, Bioorganic & medicinal chemistry letters.

Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.

S. Panowski, R. Galetto, J. Chaparro-Riggers, 2022, Cancer research.

Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models

M. Heinrich, Michael D. Kaufman, D. Flynn, 2015 .

DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study

O. Rosen, S. George, F. Janku, 2016 .

Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models

J. Fagin, Michael D. Kaufman, D. Flynn, 2015 .

Genetic selection for peptide inhibitors of angiogenin.

R. Raines, Bryan D. Smith, 2008, Protein engineering, design & selection : PEDS.

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.

J. D. de Groot, D. Flynn, S. Park, 2016, Neuro-oncology.

Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models

M. McMahon, D. Flynn, Y. Zhan, 2022, Cancer Research.